Over the past four decades, remarkable progress has been made in the treatment and prognosis of multiple myeloma (MM), although it remains an incurable disease. Chemotherapy resistance is a major hurdle for treatment efficacy. Drug resistance can be innate and so driven by genes involved in the drug metabolism pathways. We performed an association study of 71 germline variants within the major genes in those pathways (ABCB1, ABCC2, ABCG2, and their regulators NR1I2/PXR and NR1I3/ CAR) in the International Multiple Myeloma rESEarch (IMMEnSE) consortium, consisting of 1365 MM cases with survival information recruited in 5 European countries. Two of the SNPs showed a significant association with the survival of MM patients, namely rs2235013, located in ABCB1 [Hazard ratio (HR) = 1Á52, 95% confidence interval (CI) = 1Á18-1Á95, P = 0Á00087], and rs4148388, located in ABCC2 (HR = 2Á15, 95% CI = 1Á44-3Á22, P = 0Á0001). ABCC2 plays an essential role in transporting various anticancer drugs, including several used against MM, out of the cell. In silico analyses predict that the variant alleles of four SNPs in linkage disequilibrium with ABCC2-rs4148388 are associated with increased gene expression. Overexpression of ABCC2 increases drug clearance and therefore may induce drug resistance mechanisms. In conclusion, we found a promising association between ABCC2-rs4148388 and MM outcome that is supported by a plausible biological explanation.
Multiple Myeloma (MM) is a plasma cell malignancy, usually infiltrating the bone marrow, which is associated -in most cases -with the production of a monoclonal immunoglobulin or its fragments (M protein) that can be detected in the blood and/or urine (Rajkumar et al, 2014) . The uncontrolled proliferation of plasma cells in the bone marrow and the release of M protein in the blood may lead to skeletal destruction, renal insufficiency and suppression of the normal production of immunoglobulin (R€ ollig et al, 2015) . MM is the second most frequent haematological malignancy with an age-adjusted incidence of 6 per 100 000 per year in Europe and a median age at diagnosis of 69 years (Kazandjian, 2016) .
In recent decades, remarkable progress has been made in the understanding of the biology and pathogenesis of MM which, in turn, led to significant improvements in disease treatment and patient survival. However, despite these improvements, MM remains an incurable disease that is characterized by a considerable heterogeneity in patient survival. Genetic germline variants have been studied as prognostic factors for MM development and progression. Alongside two loci identified through genome-wide association studies (GWAS) (Ziv et al, 2015; Johnson et al, 2016) several studies have proposed single nucleotide polymorphisms (SNPs) to be associated with MM survival (Erickson et al, 2016; R ıos-Tamayo et al, 2016; Jakobsen Falk et al, 2018) .
As for many other cancer types, a major hurdle for MM treatment efficacy is represented by resistance to chemotherapy. This phenomenon can be innate or may develop after a prolonged exposure to chemotherapeutic agents and involves many molecular processes, especially detoxification mechanisms (Hassen et al, 2015) . To improve our knowledge on MM prognosis, and with the final goal of an individualized therapy that takes patient genotype into account, we investigated the genetic variants in five of the most important genes involved in xenobiotic metabolism: ATP-binding cassette (ABC) transporters (ABCB1, ABCC2, ABCG2), nuclear receptor subfamily 1 group I member 2 (NR1I2, also known as PXR) and nuclear receptor subfamily 1 group I member 3 (NR1I3, also known as CAR). The function of ABC transporters is to decrease the concentration of xenobiotic compounds, including chemotherapeutic drugs, inside the cell. This mechanism could lead to the development of drug resistance (Fletcher et al, 2016) . NR1I2 and NR1I3 belong to the nuclear receptors subfamily 1 and have a leading role in regulating the expression of genes involved in the xenobiotic metabolism and drug transport (Yan & Xie, 2016) . The genetic variants of transporters and their regulators can lead to changes in the efficiency of the detoxification mechanism, as demonstrated by their effect on the risk of developing various cancer types (Campa et al, 2012a,b; Martino et al, 2012a Martino et al, , 2013 Fletcher et al, 2016) and outcome. We investigated 71 SNPs belonging to the candidate genes in relation to measures of outcome of MM patients, within the International Multiple Myeloma rESEarch (IMMEnSE) consortium.
Material and methods

Study population
The study population studied consisted of patients treated in the participating institutions of the IMMEnSE consortium and has been extensively described elsewhere (Martino et al, 2012b) . Epidemiological and clinico-pathological characteristics, including age, gender, country of origin, disease stage (Durie-Salmon and/or International Staging System [ISS]; [Hari et al, 2009] ), type of therapy, response to therapy, progression-free survival (PFS) and overall survival (OS), were retrospectively collected from medical records in each participating institution. This particular study analysed 1365 subjects, of which 1329 were staged according to the DurieSalmon system only, 1096 had ISS stage only and 1050 had data for both (Table I) . Written informed consent was obtained from each participant and approval for collection and use of the samples was obtained from local Institutional Review Boards.
SNP selection
We selected 71 SNPs in 5 genes involved in drug and xenobiotic metabolism and transport, in particular: ABCB1 (SNPs = 26), ABCC2 (SNPs = 12), ABCG2 (SNPs = 16), NR1I2 (SNPs = 10) and NR1I3 (SNPs = 7). Using a tagging approach, we selected SNPs with a minor allele frequency (MAF) ≥ 5% in Caucasians from the International HapMap Project (International HapMap Consortium, 2003) . Tagging SNPs were selected using the Tagger algorithm available through Haploview (Barrett et al, 2005) , using a pairwise SNP selection with a minimum r 2 threshold of 0Á8. The complete list of SNPs is shown in Table II .
Genotyping and quality control
We performed a two-phase study. In phase 1, genotyping was conducted in 275 MM cases according to previously performed studies on MM risk Martino et al, 2013) . For phase two, DNAs were extracted from peripheral blood using using QIAamp 96 DNA QIAcube HT Kit and kept frozen till used. Genotyping was performed in 384-well plates using TaqMan (Thermo Fisher Scientific Inc., Waltham, MA, USA) or KASP (LGC Genomics, Teddington, UK) SNP genotyping assays. For quality control, about 5% of the samples were duplicated by interspersing them in the plates. Samples with a call rate lower than 75% were discarded.
Statistical analysis
Survival analysis was performed with Cox regression, calculating hazard ratios (HR) and confidence intervals (CI) using OS, PFS and response to first line therapy as end points. OS was defined as the time interval between MM diagnosis and death or the last date when the patient was still alive. PFS was defined as the time interval between autologous stem cell transplantation (ASCT) or the end of the high dose treatments (for patients non-eligible for ASCT) until documented progression or until the last progression-free examination. All analyses were adjusted for age at diagnosis, gender, region of origin, MM stage (according to the Durie-Salmon system and ISS) and therapy, defined as first-line treatment based on bortezomib/immunomodulatory drugs ('new treatments') or any other regimen (such as vincristine/adriamycin/dexamethasone or melphalan/prednisone, 'old treatments'). This distinction (old vs. new drugs) has already been successfully used in another study (Ziv et al, 2015) . The statistical analysis was performed using a co-dominant, dominant and recessive inheritance models.
In the second phase of the study, we selected those SNPs that showed a statistically significant association with MM survival, considering P < 0Á01 as an arbitrary threshold for statistical significance (see Table II ), in at least one of the analyses performed, and genotyped them in an additional set of 1054 MM patients.
Finally, we merged the two datasets for the SNPs genotyped in the second phase. For this latter phase, the threshold of statistical significance was set using the M eff method that computes the number of independent SNPs (Nyholt, 2004) . The M eff value was calculated by totalling the values for each gene (ABCB1 = 16, ABCC2 = 8, ABCG2 = 9, NR1I2 = 8, NR1I3 = 9) resulting in 44. Taking into account the 3 models of inheritance tested, the threshold of statistical significance was as follows: 0Á05/44*3 = 0Á00038.
Bioinformatic analysis
Several bioinformatic tools were used to assess the possible functional relevance of the SNPs showing the most significant associations with MM survival. To identify the regulatory potential of each SNPs and the regions nearby we used RegulomeDB (http://regulome.stanford.edu/; Boyle et al, 2012) and HaploReg (http://archive.broadinstitute.org/ma mmals/haploreg/haploreg.php; Ward & Kellis, 2016) . GTEx (http://www.gtexportal.org/home/; GTEx Consortium, 2013) was used to identify potential associations between the SNP and expression levels of nearby genes (eQTL). Analyses were performed in all tissues available in the dataset.
Results
Data filtering
After QC, the average SNP call rate was 98%, the minimum call rate observed was 87Á82% (rs2580873) and the maximum was 99Á70% (rs1197714). The concordance rate between duplicates was 99Á91%. The Hardy-Weinberg equilibrium was tested for all the SNPs, in 1133 controls genotyped in the first phase of the study, as reported in Martino et al, 2012a Martino et al, , 2013 . Table II shows the complete list of the SNPs investigated in the study and those that were replicated in the second phase. Among the 71 initial SNPs, 9 passed the selection for the second phase: in particular, 4 SNPs in the ABC genes (ABCB1-rs2235013, ABCC2 -rs4148388, -rs3740073, -rs3740067), 4 in NR1I2 (rs11917714, rs12488820, rs3732359, rs1357459) and 1 in NR1I3 (rs11265571). These SNPs were selected for their association (P < 0Á01) with at least one of the studied endpoints.
SNP associations
Considering the threshold for statistical significance (P < 0Á0003814), one polymorphism was associated with MM outcome and one showed an association very close to the significant threshold in the pooled analyses (phase one plus phase two). Specifically, ABCC2-rs4148388 showed an association between the G/G genotype and a worse OS compared to the carriers of the more common allele (HR = 2Á15, 95% CI 1Á44-3Á22, P = 0Á0001). Additionally, homozygous carriers of the A allele of ABCB1-rs2235013 showed a worse PFS compared to the other homozygotes (HR = 1Á52, 95% CI 1Á18-1Á95, P = 0Á00087). Figures 1 and 2 show the Table II . SNPs included in this study.
Gene
SNPs selected rs7789645, rs998671, rs3842, rs17064, rs6979885, rs1045642, rs7787082, rs12720066, rs1922242, rs2235013*, rs868755, rs2235023, rs10256836, rs12334183, rs10264990, rs1202172, rs17327442, rs1202184, rs17327624, rs3789243, rs2235074, rs9282564, rs2214102, rs13233308, rs10276499 , rs10267099 ABCC2 rs717620, rs7393105, rs4148388*, rs2756109, rs11190291, rs3740073*, rs4077146, rs7476245, rs3740067*, rs3740065, rs8187710, rs11190297 ABCG2 rs2728124, rs4148157, rs2231148, rs2054576, rs12505410, rs2622621, rs13120400, rs1481012, rs2725256, rs2231142, rs3114018, rs3109823, rs6857600, rs2725248, rs17731799, rs9999111 NR1I2/PXR rs10511395, rs1054190, rs11917714*, rs12488820*, rs13071341, rs2461818, rs3237359, rs13059232, rs3732357 † , rs1357459 † NR1I3/CAR rs3003596, rs3813627, rs11265571*, rs2307418, rs2502805, rs4073054, rs4233368 *Single nucleotide polymorphisms (SNPs) that passed the selection for an association with overall survival. †SNPs associated with the response to therapy in the first phase.
ABCB1
Kaplan-Meier curves for the association between ABCC2-rs4148388 and OS and for the association between ABCB1-rs2235013 and PFS. Finally, the A allele in ABCC2-rs3740073 was associated with a worse OS in all of the phases. Although none of these associations reached the study-wide significance, the closest was observed for the merged phase (HR = 1Á52, 95% CI 1Á15-2Á02, P = 0Á004). All the above results were obtained using Durie-Salmon staging as adjustment, however we also performed the analyses using the ISS system and the results were in general agreement, as showed in Tables SI and SII.  Tables III and IV report the results of the first phase, the second phase and the merged analyses for the 9 SNPs selected for replication. Results of all analyses performed in the first and second phase of the study are included in Tables SI-SVIII. We did not find any significant association between the SNPs under investigation and response to first line therapy in the merged analyses (Table SVIII) .
Bioinformatic analysis
We used several bioinformatic tools to predict possible functional relevance for the SNPs showing the most significant associations with MM outcome. Four SNPs in linkage disequilibrium (LD) with rs4148388 (r 2 = 1) had a low RegulomeDB score, specifically rs2756107 was 2b and rs2180989, rs2756102 and rs4148397 were 3a. A score of 2b indicates that the polymorphism probably affects the binding to transcription factors and denotes a region with a high sensitivity to DNAse (DNAse footprint), while 3a indicates an increased probability that the SNP affects the binding although to a lesser extent than 2b (Boyle et al, 2012) . In addition, according to GTEx, ABCC2-rs4148388 and the related SNPs are associated with the expression of ABCC2 in the mucosa of the oesophagus (P = 1Á6 9 10 À6 ).
ABCC2-rs3740073 is associated with ABCC2 expression in colon-sigmoid tissue (P = 4Á0 9 10 À6 ). For both genes the homozygotes for the minor allele were associated with increased expression in comparison with the heterozygotes and the common homozygotes. ABCB1-rs2235013 and all the SNPs in LD with this showed a maximum score of 5 in RegulomeDB, which means a minimal binding evidence. For this SNP, the GTEx software shows an association between the T/T genotype and a lower expression of ABCB1 in the testis tissue (P = 0Á000043).
Discussion
Members of the ABC transporter family are major determinants of drug resistance as they limit bioavailability of various drugs by influencing their adsorption, distribution and elimination or restricting permeabilization through blood-tissue barriers (Cascorbi & Haenisch, 2010) . We analysed the possible associations between SNPs in key genes of the xenobiotic transport pathway and their regulators with the clinical outcome of MM patients.
The strongest statistical association was found between carriers of the variant allele of ABCC2-rs4148388 and poor OS (P = 0Á0001) (Fig 1) . The ABCC2 gene plays an essential role in transporting various anticancer drugs outside the target cell, including several used against MM, for example doxorubicin, etoposide, vincristine and vinblastine (van der Schoor et al, 2015) . Overexpression of the gene increases drug clearance and therefore may induce drug resistance mechanisms (Sandusky et al, 2002) . In silico analyses with RegulomeDB and GTEx suggest that four SNPs (rs2756107, rs2180989, rs2756102 and rs4148397) in LD with ABCC2- 
95% CI, 95% confidence interval; HR, hazard ratio; HR het, hazard ratio (heterozygous); HR hom, hazard ratio (homoozygous); SNP, single nucleotide polymorphism.
All analyses were adjusted for region, gender, age at diagnosis, stage (Durie-Salmon) and first line therapy. Bold values show significant results (p < 0.05). rs4148388 are functional. These variants are predicted to affect transcription factor binding to DNA and affect ABCC2 expression: in particular, the variant alleles of all the significantly-associated SNPs are associated with increased gene expression. Therefore, the statistical association that we observed can be explained by a biological mechanism, i.e. the homozygous carrier of the G allele of ABCC2-rs4148388 SNP is associated with worse survival due to increased expression of the gene that facilitates drug elimination. In agreement with our results, Cecchin et al (2013) reported that rs4148396, which is in LD with rs4148388 (r 2 = 0Á695 in Caucasians of the 1000 Genomes Project), was associated with a poor survival in colorectal cancer patient. In addition, it is interesting to note that the associations found for this SNP were consistent across all the phases of the study, despite the heterogeneity of geographic origin and treatment regimens of our study patients. The A/A genotype of ABCB1-rs2235013 was associated with a better OS in the first phase but with a worse PFS in the following phases of the study compared with the reference genotype (G/G). The only association that approached the study-wise significance threshold (P < 0Á00038) is worse PFS (P = 0Á00087) conducted within the larger sample size (Fig 2) . Although there is evidence of the correlation between ABCB1 expression and treatment response and survival rates in tumour cancer patients (Coyle et al, 2015; Kim et al, 2016) , we did not find a functional link between ABCB1-rs2235013 and the gene expression. However, Weissfeld et al (2014) reported that carriers of the T allele of ABCB1-rs2235013 showed better lung cancer survival, in agreement with the results of our OS phase but in disagreement with our PFS results. Therefore, even though the results found are difficult to explain, they are potentially interesting also in light of that found in the literature (Weissfeld et al, 2014; Coyle et al, 2015; Kim et al, 2016) and certainly indicate that further investigation on the functional relevance of ABCB1-rs2235013 is needed given its possible role in cancer survival. A recent study (Jakobsen Falk et al, 2018) investigated the possible role of some ABCB1 SNPs in the outcome of 90 relapsed or refractory MM patients. Although ABCB1-rs2235013 was not included in that study, it is in relatively high LD with rs2032582, one of the SNPs investigated by Jakobsen Falk et al (2018) (r 2 = 0Á738). That study, which did not find any significant association between rs2032582 and MM outcome, is not directly comparable with ours because of the different sample size and the different characteristics of the MM patients (1365 unselected MM cases in our study compared to 90 relapsed or refractory MM patients reported by Jakobsen Falk et al, 2018) . The main strength of this study is the large sample size. Possible limitations include the fact that, given the high LD between the ABCC2 SNPs, it is not possible to clearly identify the variant responsible for the diversified prognosis and further studies are warranted to unravel this.
In conclusion, we found a promising association between ABCC2-rs4148388 and MM outcome that is supported by a plausible biological explanation. If this association is confirmed, a detailed analysis of the functional relevance of this SNP is warranted.
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